Unique ID issued by UMIN | UMIN000012052 |
---|---|
Receipt number | R000014089 |
Scientific Title | Prophylaxis and treatment Effects of Rikkunshito(TJ-43) on delayed gastric emptying (DGE) and gastrointestinal symptoms after pancreatoduodenectomy. |
Date of disclosure of the study information | 2013/11/01 |
Last modified on | 2023/10/24 12:35:54 |
Prophylaxis and treatment Effects of Rikkunshito(TJ-43) on delayed gastric emptying (DGE) and gastrointestinal symptoms after pancreatoduodenectomy.
The Effects of Rikkunshito on DGE and gastrointestinal symptoms after pancreatoduodenectomy.
Prophylaxis and treatment Effects of Rikkunshito(TJ-43) on delayed gastric emptying (DGE) and gastrointestinal symptoms after pancreatoduodenectomy.
The Effects of Rikkunshito on DGE and gastrointestinal symptoms after pancreatoduodenectomy.
Japan |
Disease which needs to undergo pancreatoduodenectomy (carcinoma of the head of the pancreas, bile duct carcinoma, Papilla Vater carcinoma, duodenal carcinoma, etc.)
Hepato-biliary-pancreatic medicine | Surgery in general | Gastrointestinal surgery |
Hepato-biliary-pancreatic surgery |
Malignancy
NO
To evaluate the efficacy of Rikkunshito(TJ-43) on DGE and gastrointestinal symptoms after pancreatoduodenectomy.
Efficacy
Exploratory
Pragmatic
Not applicable
Occurrence rate of DGE in patients underwent with pancreatoduodenectomy
1) Total dietary intake(TDI) after pancreatoduodenectomy
2) Gastrointestinal symptoms after pancreatoduodenectomy
3) The measurement of circulating gastrointestinal hormone(insulin, c-peptide, gastrin, glucagon and ghrelin)
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Oral administration of Rikkunshito
(2.5g t.i.d) before meals for 21 days.
However, Rikkunshito(2.5g t.i.d) were administered as a diluent via enteral feeding tube on postoperative day 1-4.
20 | years-old | <= |
80 | years-old | > |
Male and Female
1) Patients are scheduled to undergo pancreatoduodenectomy.
2) Performance Status(ECOG) of 0 to 1 cases.
3) Age:20<80
4) Sex, inpatient or outpatient: Not matter
5) All patients provided written informed consent before initiation of study-related procedures.
1) Patient with active double cancer
2) Patient who has been undergoing chemotherapy
3) Patient who receives KAMPO medicine two weeks before treatment of rikkunshito
4) Patients with serious complications (liver, kidney, heart, blood, or metabolic disorders)
5) Patient with serious hypersensitivity
6) Pregnancy or lactation woman. Patients who hope pregnancy during study
7) Patients considered inappropriate by the study investigator
50
1st name | |
Middle name | |
Last name | Yasutoshi Kimura |
Sapporo Medical University
Department of Surgery, Surgical Oncology and science
291-Nshi16, Minami1jo, Chuo-ku, Sapporo, Hokkaido
011-611-2111
kimuray@sapmed.ac.jp
1st name | |
Middle name | |
Last name | Yasutoshi Kimura |
Sapporo Medical University
Department of Surgery, Surgical Oncology and science
291-Nshi16, Minami1jo, Chuo-ku, Sapporo, Hokkaido
011-611-2111
kimuray@sapmed.ac.jp
Sapporo Medical University
Japan Society for the Promotion of Science
Other
Japan
NO
札幌医科大学(北海道)
2013 | Year | 11 | Month | 01 | Day |
Unpublished
Preinitiation
2013 | Year | 07 | Month | 01 | Day |
2013 | Year | 11 | Month | 01 | Day |
2015 | Year | 06 | Month | 30 | Day |
2013 | Year | 10 | Month | 16 | Day |
2023 | Year | 10 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014089